Clinical trial • Phase I • Oncology|Haematology
NX-5948 for Relapsed or refractory B-cell malignancies | Diffuse large B-cell lymphoma | Mantle cell lymphoma | Follicular lymphoma | Marginal zone lymphoma | Splenic marginal zone lymphoma | B-cell chronic lymphocytic leukemia | Waldenström macroglobulinemia | Primary central nervous system lymphoma | B-cell small lymphocytic lymphoma
Phase I trial of NX-5948 for Relapsed or refractory B-cell malignancies | Diffuse large B-cell lymphoma | Mantle cell lymphoma | Follicular lymphoma | Mar…
Overview
- Trial Therapeutic Area
- Oncology|Haematology
- Trial Disease
- Relapsed or refractory B-cell malignancies | Diffuse large B-cell lymphoma | Mantle cell lymphoma | Follicular lymphoma | Marginal zone lymphoma | Splenic marginal zone lymphoma | B-cell chronic lymphocytic leukemia | Waldenström macroglobulinemia | Primary central nervous system lymphoma | B-cell small lymphocytic lymphoma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 14-02-2024
- First CTIS Authorization Date
- 07-03-2024
Trial design
Phase I trial in Netherlands, France, Italy and others.
- Target Sample Size
- 322
Recruitment
- Planned Sample Size
- 322
- Recruitment Window Months
- 40
Geography
- Total Number Of Sites
- 32
- Total Number Of Participants
- 250
Netherlands
- Earliest CTIS Part Ii Submission Date
- 22-02-2024
- Latest Decision Or Authorization Date
- 07-06-2024
- Processing Time Days
- 106
- Number Of Sites
- 4
- Number Of Participants
- 40
Sites
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Hematology
- Principal Investigator Name
- Marcel Nijland
- Principal Investigator Email
- m.nijland@umcg.nl
- Contact Person Name
- Marcel Nijland
- Contact Person Email
- m.nijland@umcg.nl
- Site Name
- Universitair Medisch Centrum Utrecht
- Department Name
- Hematology
- Principal Investigator Name
- Astrid Pulles
- Principal Investigator Email
- a.e.pulles-3@umcutrecht.nl
- Contact Person Name
- Astrid Pulles
- Contact Person Email
- a.e.pulles-3@umcutrecht.nl
- Site Name
- Radboud universitair medisch centrum / RADBOUDUMC
- Department Name
- Hematology
- Principal Investigator Name
- Wendy Stevens
- Principal Investigator Email
- wendy.stevens@radboudumc.nl
- Contact Person Name
- Wendy Stevens
- Contact Person Email
- wendy.stevens@radboudumc.nl
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- Hematology
- Principal Investigator Name
- Jeanette Doorduijn
- Principal Investigator Email
- j.doorduijn@erasmusmc.nl
- Contact Person Name
- Jeanette Doorduijn
- Contact Person Email
- j.doorduijn@erasmusmc.nl
France
- Earliest CTIS Part Ii Submission Date
- 03-09-2024
- Latest Decision Or Authorization Date
- 12-09-2024
- Processing Time Days
- 9
- Number Of Sites
- 7
- Number Of Participants
- 40
Sites
- Site Name
- Centre Hospitalier Universitaire D Angers
- Department Name
- Services des Maladies du sang
- Principal Investigator Name
- Aline Clavert
- Principal Investigator Email
- aline.clavert@chu-angers.fr
- Contact Person Name
- Aline Clavert
- Contact Person Email
- aline.clavert@chu-angers.fr
- Site Name
- Centre Hospitalier Universitaire De Poitiers
- Department Name
- Hematology
- Principal Investigator Name
- Cecile Tomowiak
- Principal Investigator Email
- cecile.tomowiak@chu-poitiers.fr
- Contact Person Name
- Cecile Tomowiak
- Contact Person Email
- cecile.tomowiak@chu-poitiers.fr
- Site Name
- Hôpital Haut-Lévêque
- Department Name
- Hematology and Cell Therapy
- Principal Investigator Name
- Kamal-Krimo Bouabdallah
- Principal Investigator Email
- krimo.bouabdallah@chu-bordeaux.fr
- Contact Person Name
- Kamal-Krimo Bouabdallah
- Contact Person Email
- krimo.bouabdallah@chu-bordeaux.fr
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- Clinical Hematology
- Principal Investigator Name
- Benoit Tessoulin
- Principal Investigator Email
- benoit.tessoulin@chu-nantes.fr
- Contact Person Name
- Benoit Tessoulin
- Contact Person Email
- benoit.tessoulin@chu-nantes.fr
- Site Name
- CHRU De Nancy
- Department Name
- Hematology
- Principal Investigator Name
- Pierre Feugier
- Principal Investigator Email
- p.feugier@chru-nancy.fr
- Contact Person Name
- Pierre Feugier
- Contact Person Email
- p.feugier@chru-nancy.fr
- Site Name
- Hôpital Avicenne
- Department Name
- Unite de Recherche Clinique/ Centre de Recherche Clinique
- Principal Investigator Name
- Vincent Levy
- Principal Investigator Email
- vincent.levy@aphp.fr
- Contact Person Name
- Vincent Levy
- Contact Person Email
- vincent.levy@aphp.fr
- Site Name
- Institut Curie
- Department Name
- Oncology
- Principal Investigator Name
- Clementine Sarkozy
- Principal Investigator Email
- clementine.sarkozy@curie.fr
- Contact Person Name
- Clementine Sarkozy
- Contact Person Email
- clementine.sarkozy@curie.fr
Italy
- Earliest CTIS Part Ii Submission Date
- 11-09-2024
- Latest Decision Or Authorization Date
- 17-09-2024
- Processing Time Days
- 6
- Number Of Sites
- 7
- Number Of Participants
- 40
Sites
- Site Name
- ASST Spedali Civili di Brescia
- Department Name
- Hematology
- Principal Investigator Name
- Alessandra Tucci
- Principal Investigator Email
- alessandra.tucci@asst-spedalicivili.it
- Contact Person Name
- Alessandra Tucci
- Contact Person Email
- alessandra.tucci@asst-spedalicivili.it
- Site Name
- Azienda Ospedaliero-Universitaria Ss.Antonio E Biagio E C.Arrigo Alessandria
- Department Name
- SCDU Hematology
- Principal Investigator Name
- Marco Ladetto
- Principal Investigator Email
- marco.ladetto@uniupo.it
- Contact Person Name
- Marco Ladetto
- Contact Person Email
- marco.ladetto@uniupo.it
- Site Name
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Department Name
- Oncology and Hematology
- Principal Investigator Name
- Luca Laurenti
- Principal Investigator Email
- luca.laurenti@unicatt.it
- Contact Person Name
- Luca Laurenti
- Contact Person Email
- luca.laurenti@unicatt.it
- Site Name
- San Raffaele Hospital
- Department Name
- Strategic Research Program on CLL
- Principal Investigator Name
- Paola Ghia
- Principal Investigator Email
- ghia.paolo@hsr.it
- Contact Person Name
- Paola Ghia
- Contact Person Email
- ghia.paolo@hsr.it
- Site Name
- IRCCS Azienda Ospedaliero Universitaria - Policlinico di Sant'Orsola
- Department Name
- Dipartimento Malattie Oncologiche ed Ematologiche
- Principal Investigator Name
- Pier Zinzani
- Principal Investigator Email
- pierluigi.zinzani@unibo.it
- Contact Person Name
- Pier Zinzani
- Contact Person Email
- pierluigi.zinzani@unibo.it
- Site Name
- IRCCS San Raffaele Scientific Institute
- Department Name
- Oncology and Onco-hematology
- Principal Investigator Name
- Andrés Ferreri
- Principal Investigator Email
- ferreri.andres@hsr.it
- Contact Person Name
- Andrés Ferreri
- Contact Person Email
- ferreri.andres@hsr.it
- Site Name
- IRCCS San Raffaele Scientific Institute (secondary entry)
- Department Name
- Oncology and Onco-hematology
- Principal Investigator Name
- Andrés Ferreri
- Principal Investigator Email
- ferreri.andres@hsr.it
- Contact Person Name
- Andrés Ferreri
- Contact Person Email
- ferreri.andres@hsr.it
Poland
- Earliest CTIS Part Ii Submission Date
- 21-08-2024
- Latest Decision Or Authorization Date
- 22-09-2024
- Processing Time Days
- 32
- Number Of Sites
- 9
- Number Of Participants
- 90
Sites
- Site Name
- Wroclaw Medical University
- Department Name
- Hematology
- Principal Investigator Name
- Tomasz Wróbel
- Principal Investigator Email
- tomaszwrobel@wp.pl
- Contact Person Name
- Tomasz Wróbel
- Contact Person Email
- tomaszwrobel@wp.pl
- Site Name
- Pratia Onkologia Katowice
- Department Name
- Hematology
- Principal Investigator Name
- Sebastian Grosicki
- Principal Investigator Email
- sgrosicki@wp.pl
- Contact Person Name
- Sebastian Grosicki
- Contact Person Email
- sgrosicki@wp.pl
- Site Name
- Mtz Clinical Research Powered By Pratia
- Department Name
- Hematology
- Principal Investigator Name
- Iwona Hus
- Principal Investigator Email
- badacz@pratia.com
- Contact Person Name
- Iwona Hus
- Contact Person Email
- badacz@pratia.com
- Site Name
- Pratia MCM Krakow
- Department Name
- Lymphoid Malignancy Department
- Principal Investigator Name
- Wojciech Jurczak
- Principal Investigator Email
- wojciech.jurczak@pratia.com
- Contact Person Name
- Wojciech Jurczak
- Contact Person Email
- wojciech.jurczak@pratia.com
- Site Name
- Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
- Department Name
- Oncology
- Principal Investigator Name
- Joanna Romejko–Jarosińska
- Principal Investigator Email
- joanna.romejko-jarosinska@pib-nio.pl
- Contact Person Name
- Joanna Romejko–Jarosińska
- Contact Person Email
- joanna.romejko-jarosinska@pib-nio.pl
- Site Name
- Aidport Sp. z o.o.
- Department Name
- Hematology
- Principal Investigator Name
- Michal Kwiatek
- Principal Investigator Email
- michal.kwiatek@aidport.pl
- Contact Person Name
- Michal Kwiatek
- Contact Person Email
- michal.kwiatek@aidport.pl
- Site Name
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
- Department Name
- Hematology
- Principal Investigator Name
- Krzysztof Giannopoulos
- Principal Investigator Email
- krzysztof.giannopoulos@gmail.com
- Contact Person Name
- Krzysztof Giannopoulos
- Contact Person Email
- krzysztof.giannopoulos@gmail.com
- Site Name
- Pratia site (Warsaw)
- Department Name
- Hematology
- Principal Investigator Name
- Iwona Hus
- Principal Investigator Email
- badacz@pratia.com
- Contact Person Name
- Iwona Hus
- Contact Person Email
- badacz@pratia.com
- Site Name
- Pratia MCM Krakow (additional entry)
- Department Name
- Lymphoid Malignancy Department
- Principal Investigator Name
- Wojciech Jurczak
- Principal Investigator Email
- wojciech.jurczak@pratia.com
- Contact Person Name
- Wojciech Jurczak
- Contact Person Email
- wojciech.jurczak@pratia.com
Spain
- Earliest CTIS Part Ii Submission Date
- 21-08-2024
- Latest Decision Or Authorization Date
- 23-09-2024
- Processing Time Days
- 33
- Number Of Sites
- 5
- Number Of Participants
- 40
Sites
- Site Name
- Hospital Universitario Fundación Jiménez Díaz
- Department Name
- Hematology
- Principal Investigator Name
- Daniel Morillo Giles
- Principal Investigator Email
- dmorillo@startmadrid.com
- Contact Person Name
- Daniel Morillo Giles
- Contact Person Email
- dmorillo@startmadrid.com
- Site Name
- Hospital Universitario De Cabueñes
- Department Name
- Hematology
- Principal Investigator Name
- Ruben Fernandez-Alvarez
- Principal Investigator Email
- rubenfalva@gmail.com
- Contact Person Name
- Ruben Fernandez-Alvarez
- Contact Person Email
- rubenfalva@gmail.com
- Site Name
- Hospital Clínic Barcelona
- Department Name
- Hematology
- Principal Investigator Name
- Pablo Mozas
- Principal Investigator Email
- mozas@clinic.cat
- Contact Person Name
- Pablo Mozas
- Contact Person Email
- mozas@clinic.cat
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Hematology
- Principal Investigator Name
- Pablo Abrisqueta
- Principal Investigator Email
- pabrisqueta@vhio.net
- Contact Person Name
- Pablo Abrisqueta
- Contact Person Email
- pabrisqueta@vhio.net
- Site Name
- Hospital Universitario Ramón y Cajal
- Department Name
- Hematology
- Principal Investigator Name
- Javier Lopez-Jimenez
- Principal Investigator Email
- jljimenez@salud.madrid.org
- Contact Person Name
- Javier Lopez-Jimenez
- Contact Person Email
- jljimenez@salud.madrid.org
Sponsor
Primary sponsor
- Full Name
- Nurix Therapeutics Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- NX-5948
Related trials
Other published trials that may interest you.
- DAUNORUBICIN HYDROCHLORIDE for Acute myeloid leukemia|Relapsed or refractory acute myeloid leukemia
- Brentuximab vedotin for Peripheral T-cell lymphoma (PTCL) | Anaplastic large cell lymphoma (ALCL) | Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) | Angioimmunoblastic T-cell lymphoma (AITL) | Adult T-cell leukaemia/lymphoma (ATLL) | Enteropathy-associated T-cell lymphoma (EATL) | Hepatosplenic T-cell lymphoma | Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) | Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract | Follicular T-cell lymphoma | Nodal peripheral T-cell lymphoma with T-follicular helper phenotype
- RITUXIMAB for Diffuse large B-cell lymphoma (ABC)
- Lenalidomide for Primary central nervous system lymphoma
- Cytarabine; Daunorubicin for Myelodysplastic syndrome (higher-risk)|Oligoblastic acute myeloid leukaemia (AML)